Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer

✍ Scribed by Eddy S. Leman; Michael C. Madigan; Gisela Brünagel; Natsuki Takaha; Donald S. Coffey; Robert H. Getzenberg

• Publisher: John Wiley and Sons
• Year: 2002
• Tongue: English
• Weight: 332 KB
• Volume: 88
• Category: Article
• ISSN: 0730-2312
• DOI: 10.1002/jcb.10368

✦ Synopsis

Abstract

Nuclear shape and the underlying nuclear structure, the nuclear matrix in cancer cells. Since the NM composition is considered to maintain nuclear shape and architecture, nuclear matrix proteins (NMPs) may be involved in transformation. Our laboratory has recently characterized a subset of NMPs that are associated with prostate cancer development in the transgenic adenocarcinoma of mouse prostate (TRAMP) model. One of the identified NMPs, E3E, has a similar molecular weight (22 kDa) with a protein known as HMGI(Y). HMGI(Y) belongs to a group of non‐histone and chromatin‐associated proteins, high‐mobility‐group (HMG) proteins, and it has been shown to associate with the NM. HMGI(Y) has been reported to be elevated in different types of cancer including prostate cancer. In this study, we examined the expression of HMGI(Y) protein in the NMP composition of the TRAMP model during the progression from normal to neoplasia. The expression of HMGI(Y) in the NMP extracts of three prostatic epithelial cell lines derived from a 32‐week TRAMP mouse: TRAMP‐C1, TRAMP‐C2, and TRAMP‐C3 was also examined. Using both one‐dimensional and high‐resolution two‐dimensional immunoblot analyses, we found that: (i) HMGI(Y) is a nuclear matrix protein expressed as two protein bands with MW of 22–24 kDa and (ii) HMGI(Y) expression is correlated with neoplastic and malignant properties in late stage TRAMP prostate tumors. Overall, these findings support the evidence that HMGI(Y) can be utilized as a marker and prognostic tool for prostate cancer. © 2002 Wiley‐Liss, Inc.